Bitterroot Bio develops anti-CD47 immunotherapies to target the inflammatory processes underlying atherosclerosis, a major contributor to cardiovascular disease. By enhancing macrophage activity, these therapies aim to reduce plaque formation and the risk of heart attacks and strokes.
Funding
$145M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DFounders
Product
Problem
Atherosclerosis, a major contributor to cardiovascular disease, is driven by chronic inflammation within the arterial walls, leading to plaque formation and increasing the risk of heart attacks and strokes. Current treatments primarily address the symptoms of atherosclerosis rather than targeting the underlying inflammatory processes. This leaves a significant unmet need for therapies that can prevent plaque progression and reduce cardiovascular events.
Solution
Bitterroot Bio is developing anti-CD47 immunotherapies designed to modulate the immune response and target the inflammatory mechanisms that perpetuate atherosclerosis. By blocking the CD47 "don't eat me" signal on cells within arterial plaques, the therapy enhances macrophage activity, promoting the clearance of harmful cells and reducing plaque formation. This approach aims to stabilize or prevent the progression of atherosclerotic plaques, thereby decreasing the incidence of heart attacks and strokes. The lead candidate, BRB-002, is currently in Phase 2a clinical trials, evaluating its safety and efficacy in patients with atherosclerotic cardiovascular disease.
Target Audience
The primary target audience includes patients at risk of or diagnosed with atherosclerotic cardiovascular disease, as well as cardiologists and medical professionals seeking innovative therapies to prevent and treat atherosclerosis.
Features
- BRB-002: A novel, next-generation anti-CD47 molecule designed for atherosclerotic cardiovascular disease.
- Immunomodulatory mechanism targeting CD47 to enhance macrophage-mediated plaque clearance.
- Focus on cardio-immunology, investigating the interplay between the immune system and cardiovascular health.
- Targets the inflammatory processes underlying atherosclerosis to address the root cause of the disease.
- Clinical trials underway to evaluate safety and efficacy in human patients.